Mixed
Combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists provides additive and synergistic benefits for Cardiovascular-Kidney-Metabolic (CKM) syndrome by targeting complementary mechanisms, resulting in superior glycemic control, weight loss, and organ protection compared to monotherapy.
If you have Type 2 Diabetes, Heart Failure, Kidney Disease, or Obesity, current medical guidelines strongly support using SGLT2 inhibitors and GLP-1 receptor agonists, either alone or together, to protect your heart and kidneys. These drugs work through different mechanisms to lower blood sugar, reduce weight, and protect organs. While they can be expensive and hard to access, they are considered first-line treatments for high-risk patients. Talk to your doctor about whether combination therapy is appropriate for your specific risk profile, especially if single medications aren't enough.
The rationale behind combining the two drugs is twofold: because of their complementary mechanism of action leading to improved glycemic control and weight loss, and broader organ protection across the CKM spectrum. In other words, each agent targets different aspects of CKM syndrome. SGLT-2 inhibitors have a more pronounced renal protective effect and robust effect on heart failure hospitalization, while GLP-1 receptor agonists excel at cardiovascular protection and weight loss.
Why this rating
Supported by multiple landmark trials (EMPA-REG, LEADER, SUSTAIN-6, CREDENCE, DAPA-HF) and observational studies, though large prospective RCTs specifically for combination therapy are still pending.
Source
SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome
Aryan Gajjar et al. · Biomedicines · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →